Q2 and H1 FY26 results: revenue and profit growth, pharma strength

Ebitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

MOLDTKPAC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-8.5%Reaction day

₹790.00

prior close

₹764.80

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.5%-9.0% vs market

Packaging peers, median of 65sector-0.2%-8.4% vs sector

On the reaction day the stock moved 9.0 pts less than Nifty Microcap 250 and 8.4 pts less than its Packaging peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-0.4

15m

-2.7

30m

-4.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-8.5+0.5-9.0-0.2-8.4

Next day

-9.0+0.3-9.2-1.0-8.0

-12.2-0.1-12.1-1.0-11.1

-12.4+1.0-13.4-1.3-11.1

-11.4+0.2-11.6-1.6-9.8

-11.4-1.5-9.9-2.8-8.6

-13.2-1.5-11.8-2.6-10.6

15d

-20.3-1.7-18.6-4.8-15.5

-20.9-3.1-17.8-5.3-15.5

-22.8-6.6-16.2-6.6-16.2

-31.6-12.3-19.3-14.5-17.0

UpDownMarket · Nifty Microcap 250Sector · Packaging peers, median of 65Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board-approved unaudited Q2 and H1 FY26 results showed H1 revenue up 16.05% to Rs 450.32 crore and volume up 11.01% to 21,395 MT. Operating profit before depreciation, interest, tax and amortization rose 22.72% to Rs 86.89 crore, lifting margin to 19.3% from 18.2%. Net profit rose 23.63% to Rs 37.88 crore. Q2 pharma sales rose 45% sequentially to Rs 10.81 crore. H1 included a Rs 2.82 crore exceptional Sandila Unit gain.

Likely market impact

Growth supports sentiment, but H1 profit includes a one-off Rs 2.82 crore gain. Pharma momentum is positive; debt and capital spending need watching.